hydroxyurea has been researched along with Disease Exacerbation in 109 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Therapeutic options for patients with polycythemia vera (PV) and essential thrombocythemia (ET) resistant or intolerant to hydroxyurea are limited." | 9.19 | Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. ( Alvarez-Larrán, A; Ancochea, A; Angona, A; Antelo, ML; Bellosillo, B; Besses, C; Burgaleta, C; Cervantes, F; Durán, MA; Ferrer-Marín, F; Gómez, M; Gómez-Casares, MT; Hernández-Boluda, JC; Marcote, B; Martínez-Avilés, L; Martínez-Trillos, A; Mata, MI; Senín, A; Vicente, V; Xicoy, B, 2014) |
| "We prospectively evaluated the efficacy and safety of imatinib plus hydroxyurea in patients with progressive/recurrent meningioma." | 9.16 | Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. ( Coan, A; Desjardins, A; Drappatz, J; Friedman, HS; Gururangan, S; Herndon, JE; Lipp, ES; McLendon, RE; Norden, AD; Norfleet, JA; Peters, KB; Reardon, DA; Sampson, JH; Vredenburgh, JJ; Wen, PY, 2012) |
| "We performed a phase II study to evaluate the combination of imatinib mesylate, an adenosine triphosphate mimetic, tyrosine kinase inhibitor, plus hydroxyurea, a ribonucleotide reductase inhibitor, in patients with recurrent glioblastoma multiforme (GBM)." | 9.11 | Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. ( Badruddoja, MA; Desjardins, A; Dowell, JM; Dresemann, G; Egorin, MJ; Friedman, AH; Friedman, HS; Gururangan, I; Gururangan, S; Herndon, JE; Kicielinski, KP; Lagattuta, TF; McLendon, RE; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Salvado, AJ; Sampson, JH; Sathornsumetee, S; Vredenburgh, JJ, 2005) |
| "Although tumor regression appears uncommon, these results indicate that hydroxyurea may arrest progression of unresectable or recurrent benign meningiomas." | 9.10 | Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. ( Abrey, LE; Cruz, CR; Gentili, F; Hariharan, S; Macdonald, DR; Mason, WP, 2002) |
| " levofolinic acid and oral hydroxyurea on a weekly schedule is well tolerated by the vast majority of patients with locally advanced and/or metastatic carcinoma of the pancreas or the gallbladder." | 9.08 | Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). ( Colucci, G; Fortunato, S; Gebbia, N; Gebbia, V; Giotta, F; Giuseppe, S; Majello, E; Pezzella, G; Riccardi, F; Testa, A, 1996) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 8.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| "Hydroxyurea is an old drug that is often used to control essential thrombocythemia and polycythemia vera in patients with high-risk disease." | 8.83 | Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia. ( Dingli, D; Tefferi, A, 2006) |
| "The prevalence of albuminuria was lower among patients on hydroxyurea (34." | 7.80 | Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease. ( Ataga, KI; Derebail, VK; Desai, PC; Laurin, LP; Nachman, PH, 2014) |
| "The leukemogenic risk attributed to therapy of polycythemia vera with radiophosphorus and alkylating drugs has led, over the last 20 years, to the increased use of myelosupressive nonmutagenic drugs, especially hydroxyurea." | 7.71 | Leukemic transformation of polycythemia vera after treatment with hydroxyurea with abnormalities of chromosome 17. ( Fricová, M; Guman, T; Hlebasková, M; Kafková, A; Nebesnáková, E; Raffac, S; Stecová, N; Svorcová, E; Tóthová, E, 2001) |
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 7.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy." | 7.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| "Thrombotic events and disease progression were infrequent in both arms, whereas grade 3/4 adverse events were more frequent with PEG (46% vs 28%)." | 7.11 | A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. ( Arango Ossa, JE; Arcasoy, MO; Bacigalupo, A; Barbui, T; Berenzon, D; Catchatourian, R; De Stefano, V; Dueck, AC; Ewing, J; Farnoud, N; Goldberg, JD; Harrison, CN; Hoffman, R; Kessler, CM; Kiladjian, JJ; Kosiorek, HE; Kremyanskaya, M; Leibowitz, DS; Levine, MF; Marchioli, R; Mascarenhas, J; McGovern, E; McMullin, MF; Mead, AJ; Mesa, RA; Nagler, A; Najfeld, V; O'Connell, CL; Penson, AV; Prchal, JT; Price, L; Rambaldi, A; Rampal, RK; Rondelli, D; Salama, ME; Sandy, L; Silver, RT; Tognoni, G; Tripodi, J; Vannucchi, AM; Weinberg, RS; Winton, EF; Yacoub, A, 2022) |
| "4 Gy) and concurrent HU, administered for a median time of three months with a daily dosage of 20 mg/kg." | 6.43 | Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. ( Fahlbusch, R; Ganslandt, O; Grabenbauer, GG; Hahn, BM; Sauer, R; Schrell, UM, 2005) |
| "An analysis of the risk of progression towards leukemia, carcinoma and myelofibrosis was performed in 93 patients treated by 32P alone (PVSG protocols) since 1970-1979, 395 patients over the age of 65 years treated by 32P with or without maintenance therapy using hydroxyurea (French protocol) since 1980-1994, and 202 patients under the age of 65 treated by either hydroxyurea or pipobroman since 1980." | 6.18 | Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias". ( Dresch, C; Echard, M; Goguel, A; Grange, MJ; Lejeune, F; Najean, Y; Rain, JD, 1996) |
| "Hydroxyurea was given orally at an initial dose of 20 mg/kg/day (escalated up to 30 mg/kg/day as necessary, if well tolerated)." | 5.51 | Evidence of hydroxyurea activity in children with pretreated desmoid-type fibromatosis: A new option in the armamentarium of systemic therapies. ( Affinita, MC; Bisogno, G; Casanova, M; Chiaravalli, S; Corradini, N; Ferrari, A; Meazza, C; Orbach, D, 2019) |
| "Hydroxyurea has modest activity against meningiomas and should be considered for patients who are poor surgical candidates, have unresectable or large residual meningiomas, or have progressed after surgical resection or irradiation, or both." | 5.32 | Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. ( Newton, HB; Scott, SR; Volpi, C, 2004) |
| "Therapeutic options for patients with polycythemia vera (PV) and essential thrombocythemia (ET) resistant or intolerant to hydroxyurea are limited." | 5.19 | Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. ( Alvarez-Larrán, A; Ancochea, A; Angona, A; Antelo, ML; Bellosillo, B; Besses, C; Burgaleta, C; Cervantes, F; Durán, MA; Ferrer-Marín, F; Gómez, M; Gómez-Casares, MT; Hernández-Boluda, JC; Marcote, B; Martínez-Avilés, L; Martínez-Trillos, A; Mata, MI; Senín, A; Vicente, V; Xicoy, B, 2014) |
| "We prospectively evaluated the efficacy and safety of imatinib plus hydroxyurea in patients with progressive/recurrent meningioma." | 5.16 | Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. ( Coan, A; Desjardins, A; Drappatz, J; Friedman, HS; Gururangan, S; Herndon, JE; Lipp, ES; McLendon, RE; Norden, AD; Norfleet, JA; Peters, KB; Reardon, DA; Sampson, JH; Vredenburgh, JJ; Wen, PY, 2012) |
| "We performed a phase II study to evaluate the combination of imatinib mesylate, an adenosine triphosphate mimetic, tyrosine kinase inhibitor, plus hydroxyurea, a ribonucleotide reductase inhibitor, in patients with recurrent glioblastoma multiforme (GBM)." | 5.11 | Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. ( Badruddoja, MA; Desjardins, A; Dowell, JM; Dresemann, G; Egorin, MJ; Friedman, AH; Friedman, HS; Gururangan, I; Gururangan, S; Herndon, JE; Kicielinski, KP; Lagattuta, TF; McLendon, RE; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Salvado, AJ; Sampson, JH; Sathornsumetee, S; Vredenburgh, JJ, 2005) |
| "Although tumor regression appears uncommon, these results indicate that hydroxyurea may arrest progression of unresectable or recurrent benign meningiomas." | 5.10 | Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. ( Abrey, LE; Cruz, CR; Gentili, F; Hariharan, S; Macdonald, DR; Mason, WP, 2002) |
| " levofolinic acid and oral hydroxyurea on a weekly schedule is well tolerated by the vast majority of patients with locally advanced and/or metastatic carcinoma of the pancreas or the gallbladder." | 5.08 | Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). ( Colucci, G; Fortunato, S; Gebbia, N; Gebbia, V; Giotta, F; Giuseppe, S; Majello, E; Pezzella, G; Riccardi, F; Testa, A, 1996) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 4.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| "Hydroxyurea is an old drug that is often used to control essential thrombocythemia and polycythemia vera in patients with high-risk disease." | 4.83 | Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia. ( Dingli, D; Tefferi, A, 2006) |
| " Randomized studies have shown that the risk of thrombosis was significantly reduced in ET with the use of hydroxyurea (HU) and in PV with the use of chlorambucil or 32P." | 4.80 | Treatment of polycythaemia vera and essential thrombocythaemia. ( Silverstein, MN; Tefferi, A, 1998) |
| "Pegylated interferon (peg-IFN) was proven by phase II trials to be effective in polycythemia vera (PV); however, it is not clear whether it could improve patient outcome compared to hydroxyurea (HU)." | 3.85 | Can pegylated interferon improve the outcome of polycythemia vera patients? ( Beggiato, E; Benevolo, G; Boccadoro, M; Borchiellini, A; Cerrano, M; Crisà, E; Ferrero, D; Lanzarone, G; Manzini, PM; Riera, L, 2017) |
| "The prevalence of albuminuria was lower among patients on hydroxyurea (34." | 3.80 | Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease. ( Ataga, KI; Derebail, VK; Desai, PC; Laurin, LP; Nachman, PH, 2014) |
| " We describe the case of a 62-year-old man who developed precursor T-cell (pre-T) ALL 18 months after the diagnosis of an unclassifiable chronic myeloproliferative syndrome (CMPD, U), which had been treated with hydroxyurea (HU) over 12 months." | 3.74 | A case of chronic myeloproliferative syndrome followed by precursor T-cell acute lymphoblastic leukemia. ( Bacher, U; Haferlach, C; Haferlach, T; Harich, HD; Kern, W; Schnittger, S, 2007) |
| "Imatinib mesylate has been reported to produce positive results in atypical chronic myeloproliferative disorders (CMD) with chromosomal translocations that disrupt the platelet-derived growth factor receptor beta gene (PDGFRB)." | 3.72 | Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene. ( Bastie, JN; Castaigne, S; Cross, NC; Garcia, I; Mahon, FX; Terré, C, 2004) |
| "The leukemogenic risk attributed to therapy of polycythemia vera with radiophosphorus and alkylating drugs has led, over the last 20 years, to the increased use of myelosupressive nonmutagenic drugs, especially hydroxyurea." | 3.71 | Leukemic transformation of polycythemia vera after treatment with hydroxyurea with abnormalities of chromosome 17. ( Fricová, M; Guman, T; Hlebasková, M; Kafková, A; Nebesnáková, E; Raffac, S; Stecová, N; Svorcová, E; Tóthová, E, 2001) |
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 3.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy." | 3.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| "Thrombotic events and disease progression were infrequent in both arms, whereas grade 3/4 adverse events were more frequent with PEG (46% vs 28%)." | 3.11 | A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. ( Arango Ossa, JE; Arcasoy, MO; Bacigalupo, A; Barbui, T; Berenzon, D; Catchatourian, R; De Stefano, V; Dueck, AC; Ewing, J; Farnoud, N; Goldberg, JD; Harrison, CN; Hoffman, R; Kessler, CM; Kiladjian, JJ; Kosiorek, HE; Kremyanskaya, M; Leibowitz, DS; Levine, MF; Marchioli, R; Mascarenhas, J; McGovern, E; McMullin, MF; Mead, AJ; Mesa, RA; Nagler, A; Najfeld, V; O'Connell, CL; Penson, AV; Prchal, JT; Price, L; Rambaldi, A; Rampal, RK; Rondelli, D; Salama, ME; Sandy, L; Silver, RT; Tognoni, G; Tripodi, J; Vannucchi, AM; Weinberg, RS; Winton, EF; Yacoub, A, 2022) |
| "Eligible patients had newly diagnosed HNSCC." | 2.76 | A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. ( Blair, EA; Cohen, EE; Haraf, DJ; Kunnavakkam, R; Salama, JK; Seiwert, T; Stenson, KM; Vokes, EE; Williams, R; Witt, ME, 2011) |
| "Between 1999 and 2005, 130 patients with head and neck cancer were treated with salvage surgery and randomly assigned to full-dose reirradiation combined with chemotherapy (RT arm) or to observation (a "wait and see" approach; WS arm)." | 2.73 | Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. ( Bardet, E; Benhamou, E; Bensadoun, RJ; Bourhis, J; Castaing, M; de Raucourt, D; Dolivet, G; Ferron, C; Géry, B; Grégoire, V; Hamoir, M; Janot, F; Julieron, M, 2008) |
| "To achieve locoregional control of head and neck cancer, survival, and organ preservation using intensive concomitant chemoradiotherapy." | 2.69 | Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. ( Dolan, ME; Haraf, DJ; Hsieh, YC; Humerickhouse, R; Kies, MS; List, M; Mittal, BB; Pelzer, H; Stenson, K; Sulzen, L; Vokes, EE; Weichselbaum, RR; Witt, ME, 2000) |
| "Current treatment for polycythemia vera (PV) is limited and primarily targets thrombosis risk." | 2.66 | Novel agents for the treatment of polycythemia vera: an insight into preclinical research and early phase clinical trials. ( Mesa, R; Padrnos, L, 2020) |
| "The clinical course suggests that the pneumonitis was induced by hydroxycarbamide." | 2.58 | A 66-year-old man with hydroxycarbamide induced pneumonitis. ( Derichs, C; Klooster, P; Vlasveld, LT, 2018) |
| "Essential thrombocythemia is a chronic myeloproliferative neoplasm characterized by sustained thrombocytosis, bone marrow megakaryocytic hyperplasia and an increased risk of thrombosis and hemorrhage." | 2.49 | [Treatment of essential thrombocythemia]. ( Alvarez-Larrán, A; Besses, C; Cervantes, F, 2013) |
| "Treatment with busulfan or interferon-α is usually effective in hydroxyurea failures." | 2.48 | Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. ( Tefferi, A, 2012) |
| "4 Gy) and concurrent HU, administered for a median time of three months with a daily dosage of 20 mg/kg." | 2.43 | Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. ( Fahlbusch, R; Ganslandt, O; Grabenbauer, GG; Hahn, BM; Sauer, R; Schrell, UM, 2005) |
| "Hydroxyurea (HU) has a limited, if any, leukemogenic potential and should be considered the current cytotoxic drug for patients at high risk for thrombotic complications, ie, those with age above 60 years or previous thrombotic events." | 2.42 | The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? ( Barbui, T, 2004) |
| "Hydroxyurea was given orally at an initial dose of 20 mg/kg/day (escalated up to 30 mg/kg/day as necessary, if well tolerated)." | 1.51 | Evidence of hydroxyurea activity in children with pretreated desmoid-type fibromatosis: A new option in the armamentarium of systemic therapies. ( Affinita, MC; Bisogno, G; Casanova, M; Chiaravalli, S; Corradini, N; Ferrari, A; Meazza, C; Orbach, D, 2019) |
| "Risk of thrombosis is higher in JAK2-mutated ET." | 1.51 | Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2019) |
| "Clinical severity of thalassemia intermedia increases with age, with more severe anemia and more frequent complications such as extramedullary hematopoiesis and iron overload mainly related to increased intestinal absorption." | 1.40 | [Current management of thalassemia intermedia]. ( Thuret, I, 2014) |
| "Stroke and silent cerebral infarction were not related to clinical hematologic or HbF response to HU." | 1.39 | Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians. ( Calvaruso, G; Iannello, S; Maggio, A; Pecoraro, A; Rigano, P; Steinberg, MH, 2013) |
| "Indolent systemic mastocytosis is a group of rare diseases for which reliable predictors of progression and outcome are still lacking." | 1.35 | Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. ( Almeida, J; Alvarez-Twose, I; Bellas, C; Escribano, L; García-Cosío, M; Garcia-Montero, A; Jara-Acevedo, M; Núñez, R; Orfao, A; Sánchez-Muñoz, L; Teodósio, C, 2009) |
| "Controversial issues in chronic idiopathic myelofibrosis (IMP) are amongst others the evolution of the disease process and the influence of therapy on the dynamics of fibrosis." | 1.32 | Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients. ( Diehl, V; Kvasnicka, HM; Schmitt-Graeff, A; Thiele, J, 2003) |
| "Hydroxyurea has modest activity against meningiomas and should be considered for patients who are poor surgical candidates, have unresectable or large residual meningiomas, or have progressed after surgical resection or irradiation, or both." | 1.32 | Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. ( Newton, HB; Scott, SR; Volpi, C, 2004) |
| "The patient who had trisomy 8 at the time of diagnosis underwent myeloid blastic transformation in 35 months." | 1.31 | Leukemic transformation with trisomy 8 in essential thrombocythemia: a report of four cases. ( Hirose, Y; Masaki, Y; Sugai, S, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (13.76) | 18.2507 |
| 2000's | 39 (35.78) | 29.6817 |
| 2010's | 47 (43.12) | 24.3611 |
| 2020's | 8 (7.34) | 2.80 |
| Authors | Studies |
|---|---|
| Mascarenhas, J | 3 |
| Kosiorek, HE | 1 |
| Prchal, JT | 1 |
| Rambaldi, A | 1 |
| Berenzon, D | 2 |
| Yacoub, A | 1 |
| Harrison, CN | 3 |
| McMullin, MF | 4 |
| Vannucchi, AM | 2 |
| Ewing, J | 2 |
| O'Connell, CL | 1 |
| Kiladjian, JJ | 2 |
| Mead, AJ | 2 |
| Winton, EF | 1 |
| Leibowitz, DS | 1 |
| De Stefano, V | 1 |
| Arcasoy, MO | 1 |
| Kessler, CM | 1 |
| Catchatourian, R | 1 |
| Rondelli, D | 1 |
| Silver, RT | 1 |
| Bacigalupo, A | 1 |
| Nagler, A | 1 |
| Kremyanskaya, M | 2 |
| Levine, MF | 1 |
| Arango Ossa, JE | 1 |
| McGovern, E | 1 |
| Sandy, L | 1 |
| Salama, ME | 1 |
| Najfeld, V | 1 |
| Tripodi, J | 1 |
| Farnoud, N | 1 |
| Penson, AV | 1 |
| Weinberg, RS | 1 |
| Price, L | 1 |
| Goldberg, JD | 1 |
| Barbui, T | 4 |
| Marchioli, R | 1 |
| Tognoni, G | 1 |
| Rampal, RK | 2 |
| Mesa, RA | 1 |
| Dueck, AC | 2 |
| Hoffman, R | 3 |
| Monus, T | 1 |
| Howell, CM | 1 |
| Zhao, Y | 1 |
| Maule, J | 1 |
| Li, Y | 1 |
| Neff, J | 1 |
| McCall, CM | 1 |
| Hao, T | 1 |
| Yang, W | 1 |
| Rehder, C | 1 |
| Yang, LH | 1 |
| Wang, E | 1 |
| Hong, J | 1 |
| Lee, JH | 1 |
| Byun, JM | 1 |
| Lee, JY | 1 |
| Koh, Y | 1 |
| Shin, DY | 1 |
| Lee, JO | 1 |
| Hwang, SM | 1 |
| Choi, HS | 1 |
| Kim, I | 1 |
| Yoon, SS | 1 |
| Bang, SM | 1 |
| Pecker, LH | 1 |
| Silver, EJ | 1 |
| Roth, M | 1 |
| Manwani, D | 2 |
| Padrnos, L | 1 |
| Mesa, R | 2 |
| Chifotides, HT | 1 |
| Bose, P | 1 |
| Verstovsek, S | 1 |
| Minniti, CP | 1 |
| Zaidi, AU | 1 |
| Nouraie, M | 1 |
| Crouch, GD | 1 |
| Crouch, AS | 1 |
| Callaghan, MU | 1 |
| Carpenter, S | 1 |
| Jacobs, C | 1 |
| Han, J | 1 |
| Simon, J | 1 |
| Glassberg, J | 1 |
| Gordeuk, VR | 2 |
| Klings, ES | 1 |
| Kwiatkowski, J | 1 |
| Kuliszkiewicz-Janus, M | 1 |
| Rymer, W | 1 |
| Jaźwiec, B | 1 |
| Małecki, R | 1 |
| Xu, X | 1 |
| Xu, Y | 1 |
| Guo, R | 2 |
| Xu, R | 1 |
| Fu, C | 1 |
| Xing, M | 1 |
| Sasanuma, H | 1 |
| Li, Q | 1 |
| Takata, M | 1 |
| Takeda, S | 1 |
| Xu, D | 1 |
| Tang, J | 1 |
| Zhang, C | 1 |
| Lin, J | 1 |
| Duan, P | 1 |
| Long, J | 1 |
| Zhu, H | 1 |
| Park, S | 1 |
| Hamel, JF | 1 |
| Toma, A | 1 |
| Kelaidi, C | 1 |
| Thépot, S | 1 |
| Campelo, MD | 1 |
| Santini, V | 1 |
| Sekeres, MA | 1 |
| Balleari, E | 1 |
| Kaivers, J | 1 |
| Sapena, R | 1 |
| Götze, K | 1 |
| Müller-Thomas, C | 1 |
| Beyne-Rauzy, O | 1 |
| Stamatoullas, A | 1 |
| Kotsianidis, I | 1 |
| Komrokji, R | 1 |
| Steensma, DP | 1 |
| Fensterl, J | 1 |
| Roboz, GJ | 1 |
| Bernal, T | 1 |
| Ramos, F | 1 |
| Calabuig, M | 1 |
| Guerci-Bresler, A | 1 |
| Bordessoule, D | 1 |
| Cony-Makhoul, P | 1 |
| Cheze, S | 1 |
| Wattel, E | 1 |
| Rose, C | 1 |
| Vey, N | 1 |
| Gioia, D | 1 |
| Ferrero, D | 2 |
| Gaidano, G | 1 |
| Cametti, G | 1 |
| Pane, F | 1 |
| Sanna, A | 1 |
| Germing, U | 1 |
| Sanz, GF | 1 |
| Dreyfus, F | 1 |
| Fenaux, P | 1 |
| Andersen, C | 1 |
| Yadav, H | 1 |
| Iyer, VN | 1 |
| Kubesova, B | 1 |
| Pavlova, S | 1 |
| Malcikova, J | 1 |
| Kabathova, J | 1 |
| Radova, L | 1 |
| Tom, N | 1 |
| Tichy, B | 1 |
| Plevova, K | 1 |
| Kantorova, B | 1 |
| Fiedorova, K | 1 |
| Slavikova, M | 1 |
| Bystry, V | 1 |
| Kissova, J | 1 |
| Gisslinger, B | 1 |
| Gisslinger, H | 1 |
| Penka, M | 1 |
| Mayer, J | 2 |
| Kralovics, R | 1 |
| Pospisilova, S | 1 |
| Doubek, M | 1 |
| Parasramka, S | 1 |
| Talari, G | 1 |
| Rosenfeld, M | 1 |
| Guo, J | 1 |
| Villano, JL | 1 |
| Panchal, A | 1 |
| Fox, S | 1 |
| Yap, C | 1 |
| Gbandi, E | 1 |
| Houlton, A | 1 |
| Alimam, S | 1 |
| Wood, M | 1 |
| Chen, F | 1 |
| Coppell, J | 1 |
| Panoskaltsis, N | 1 |
| Knapper, S | 1 |
| Ali, S | 1 |
| Hamblin, A | 1 |
| Scherber, R | 1 |
| Cross, NCP | 1 |
| Ansari, J | 1 |
| Moufarrej, YE | 1 |
| Pawlinski, R | 1 |
| Gavins, FNE | 1 |
| Hankins, JS | 2 |
| Estepp, JH | 2 |
| Hodges, JR | 1 |
| Villavicencio, MA | 1 |
| Robison, LL | 1 |
| Weiss, MJ | 1 |
| Kang, G | 2 |
| Schreiber, JE | 1 |
| Porter, JS | 1 |
| Kaste, SC | 1 |
| Saving, KL | 1 |
| Bryant, PC | 1 |
| Deyo, JE | 1 |
| Nottage, KA | 1 |
| King, AA | 1 |
| Brandow, AM | 1 |
| Lebensburger, JD | 1 |
| Adesina, O | 1 |
| Chou, ST | 1 |
| Zemel, BS | 1 |
| Smeltzer, MP | 1 |
| Wang, WC | 2 |
| Gurney, JG | 1 |
| ElAlfy, MS | 1 |
| Adly, AAM | 1 |
| Ebeid, FSE | 1 |
| Eissa, DS | 1 |
| Ismail, EAR | 1 |
| Mohammed, YH | 1 |
| Ahmed, ME | 1 |
| Saad, AS | 1 |
| Derichs, C | 1 |
| Klooster, P | 1 |
| Vlasveld, LT | 1 |
| Godfrey, AL | 1 |
| Campbell, PJ | 1 |
| MacLean, C | 1 |
| Buck, G | 1 |
| Cook, J | 1 |
| Temple, J | 1 |
| Wilkins, BS | 1 |
| Wheatley, K | 1 |
| Nangalia, J | 1 |
| Grinfeld, J | 1 |
| Forsyth, C | 1 |
| Green, AR | 3 |
| Ferrari, A | 1 |
| Orbach, D | 1 |
| Affinita, MC | 1 |
| Chiaravalli, S | 1 |
| Corradini, N | 1 |
| Meazza, C | 1 |
| Bisogno, G | 1 |
| Casanova, M | 1 |
| Tefferi, A | 7 |
| Zahr, RS | 1 |
| Li, C | 1 |
| Lebensburger, J | 1 |
| Marcellino, B | 1 |
| Oo, ZY | 1 |
| Proctor, M | 1 |
| Stevenson, AJ | 1 |
| Nazareth, D | 1 |
| Fernando, M | 1 |
| Daignault, SM | 1 |
| Lanagan, C | 1 |
| Walpole, S | 1 |
| Bonazzi, V | 1 |
| Škalamera, D | 1 |
| Snell, C | 1 |
| Haass, NK | 1 |
| Larsen, JE | 1 |
| Gabrielli, B | 1 |
| Alvarez-Larrán, A | 2 |
| Cervantes, F | 2 |
| Besses, C | 2 |
| Sheth, S | 1 |
| Licursi, M | 1 |
| Bhatia, M | 1 |
| Rigano, P | 1 |
| Pecoraro, A | 1 |
| Calvaruso, G | 1 |
| Steinberg, MH | 1 |
| Iannello, S | 1 |
| Maggio, A | 1 |
| Pecci, A | 1 |
| Croci, G | 1 |
| Balduini, CL | 1 |
| Boveri, E | 1 |
| Fu, R | 1 |
| Zhang, L | 1 |
| Yang, R | 1 |
| Laurin, LP | 1 |
| Nachman, PH | 1 |
| Desai, PC | 1 |
| Ataga, KI | 1 |
| Derebail, VK | 1 |
| Tiziana Storlazzi, C | 1 |
| Pieri, L | 1 |
| Paoli, C | 1 |
| Daniele, G | 1 |
| Lasho, T | 1 |
| Martínez-Avilés, L | 1 |
| Hernández-Boluda, JC | 1 |
| Ferrer-Marín, F | 1 |
| Antelo, ML | 1 |
| Burgaleta, C | 1 |
| Mata, MI | 1 |
| Xicoy, B | 1 |
| Martínez-Trillos, A | 1 |
| Gómez-Casares, MT | 1 |
| Durán, MA | 1 |
| Marcote, B | 1 |
| Ancochea, A | 1 |
| Senín, A | 1 |
| Angona, A | 1 |
| Gómez, M | 1 |
| Vicente, V | 1 |
| Bellosillo, B | 1 |
| Vazquez, B | 1 |
| Shah, B | 1 |
| Zhang, X | 1 |
| Lash, JP | 1 |
| Saraf, SL | 1 |
| Björkholm, M | 1 |
| Hultcrantz, M | 1 |
| Derolf, ÅR | 1 |
| Stein, BL | 2 |
| Moliterno, AR | 2 |
| Tiu, RV | 1 |
| Thuret, I | 1 |
| Shirane, S | 1 |
| Araki, M | 1 |
| Morishita, S | 1 |
| Edahiro, Y | 1 |
| Sunami, Y | 1 |
| Hironaka, Y | 1 |
| Noguchi, M | 1 |
| Koike, M | 1 |
| Sato, E | 1 |
| Ohsaka, A | 1 |
| Komatsu, N | 1 |
| Eliaçık, E | 1 |
| Işık, A | 1 |
| Aksu, S | 1 |
| Üner, A | 1 |
| Büyükaşık, Y | 1 |
| Sayınalp, N | 1 |
| Göker, H | 1 |
| Özcebe, OI | 1 |
| Haznedaroğlu, İC | 1 |
| Aylı, M | 1 |
| Özcan, M | 1 |
| Cengiz Seval, G | 1 |
| Oh, ST | 1 |
| Hobbs, GS | 1 |
| Abboud, CN | 1 |
| Adler, K | 1 |
| Heaney, ML | 1 |
| Jabbour, EJ | 1 |
| Komrokji, RS | 1 |
| Ritchie, EK | 1 |
| Rice, L | 1 |
| Matsumoto, S | 1 |
| Ibrahim, R | 1 |
| Grégoire, JC | 1 |
| L'Allier, PL | 1 |
| Pressacco, J | 1 |
| Tardif, JC | 1 |
| Budoff, MJ | 1 |
| Crisà, E | 1 |
| Cerrano, M | 1 |
| Beggiato, E | 1 |
| Benevolo, G | 1 |
| Lanzarone, G | 1 |
| Manzini, PM | 1 |
| Borchiellini, A | 1 |
| Riera, L | 1 |
| Boccadoro, M | 1 |
| Gangat, N | 1 |
| Janot, F | 1 |
| de Raucourt, D | 1 |
| Benhamou, E | 1 |
| Ferron, C | 1 |
| Dolivet, G | 1 |
| Bensadoun, RJ | 1 |
| Hamoir, M | 1 |
| Géry, B | 1 |
| Julieron, M | 1 |
| Castaing, M | 1 |
| Bardet, E | 1 |
| Grégoire, V | 1 |
| Bourhis, J | 1 |
| Huang, CT | 1 |
| Kuo, PH | 1 |
| Yao, M | 1 |
| Tsai, YJ | 1 |
| Yang, PC | 1 |
| Escribano, L | 1 |
| Alvarez-Twose, I | 1 |
| Sánchez-Muñoz, L | 1 |
| Garcia-Montero, A | 1 |
| Núñez, R | 1 |
| Almeida, J | 1 |
| Jara-Acevedo, M | 1 |
| Teodósio, C | 1 |
| García-Cosío, M | 1 |
| Bellas, C | 1 |
| Orfao, A | 1 |
| Reddy, KS | 1 |
| Schwartz, GE | 1 |
| Jamedhor, M | 1 |
| Beer, PA | 1 |
| Turner, ML | 1 |
| Dingli, D | 1 |
| Ruggeri, M | 1 |
| Finotto, S | 1 |
| Fortuna, S | 1 |
| Rodeghiero, F | 2 |
| Salama, JK | 1 |
| Haraf, DJ | 4 |
| Stenson, KM | 1 |
| Blair, EA | 1 |
| Witt, ME | 4 |
| Williams, R | 1 |
| Kunnavakkam, R | 1 |
| Cohen, EE | 1 |
| Seiwert, T | 1 |
| Vokes, EE | 4 |
| Elbahrawy, A | 1 |
| Hamdy, M | 1 |
| Morsy, MH | 1 |
| Ragab, R | 1 |
| Reardon, DA | 3 |
| Norden, AD | 1 |
| Desjardins, A | 3 |
| Vredenburgh, JJ | 3 |
| Herndon, JE | 3 |
| Coan, A | 2 |
| Sampson, JH | 2 |
| Gururangan, S | 3 |
| Peters, KB | 2 |
| McLendon, RE | 2 |
| Norfleet, JA | 1 |
| Lipp, ES | 2 |
| Drappatz, J | 1 |
| Wen, PY | 1 |
| Friedman, HS | 3 |
| McLendon, R | 1 |
| Sathornsumetee, S | 2 |
| Rich, JN | 3 |
| Janney, D | 1 |
| Pardanani, A | 1 |
| Razga, F | 1 |
| Jurcek, T | 1 |
| Jeziskova, I | 1 |
| Zackova, D | 1 |
| Dvorakova, D | 1 |
| Borsky, M | 1 |
| Racil, Z | 1 |
| Wadman, RI | 1 |
| Bosboom, WM | 1 |
| van der Pol, WL | 1 |
| van den Berg, LH | 1 |
| Wokke, JH | 1 |
| Iannaccone, ST | 1 |
| Vrancken, AF | 1 |
| Gregory, TB | 1 |
| Brousse, V | 1 |
| Gandhi, S | 1 |
| de Montalembert, M | 1 |
| Height, S | 1 |
| Dick, MC | 1 |
| O'Driscoll, S | 1 |
| Abihsera, G | 1 |
| Rees, DC | 1 |
| Mason, WP | 1 |
| Gentili, F | 1 |
| Macdonald, DR | 1 |
| Hariharan, S | 1 |
| Cruz, CR | 1 |
| Abrey, LE | 1 |
| Buhr, T | 1 |
| Büsche, G | 1 |
| Choritz, H | 1 |
| Länger, F | 1 |
| Kreipe, H | 1 |
| Stenson, K | 3 |
| Rosen, FR | 2 |
| Kies, MS | 2 |
| Rademaker, AW | 1 |
| Brockstein, BE | 2 |
| List, MA | 2 |
| Fung, BB | 1 |
| Portugal, L | 2 |
| Mittal, BB | 3 |
| Pelzer, H | 3 |
| Weichselbaum, RR | 3 |
| Bareford, D | 1 |
| Craig, J | 1 |
| Harrison, C | 1 |
| Oscier, DG | 1 |
| Reilly, JT | 1 |
| Hishida, A | 1 |
| Yamamoto, K | 1 |
| Matsushita, T | 1 |
| Tanimoto, M | 1 |
| Saito, H | 1 |
| Emi, N | 1 |
| Royer-Pokora, B | 1 |
| Hildebrandt, B | 1 |
| Redmann, A | 1 |
| Herold, C | 1 |
| Kronenwett, R | 1 |
| Haas, R | 1 |
| Drechsler, M | 1 |
| Wieland, C | 1 |
| Thiele, J | 2 |
| Kvasnicka, HM | 2 |
| Schmitt-Graeff, A | 2 |
| Diehl, V | 2 |
| Prabhash, K | 1 |
| Loknath, D | 1 |
| Babu, KG | 1 |
| Hasib, AG | 1 |
| Biswas, S | 1 |
| Bapsy, PP | 1 |
| Argiris, A | 1 |
| Cazzola, M | 1 |
| Barosi, G | 1 |
| Grossi, A | 1 |
| Gugliotta, L | 1 |
| Liberato, LN | 1 |
| Marchetti, M | 1 |
| Mazzucconi, MG | 1 |
| Tura, S | 2 |
| Colla, S | 1 |
| Sammarelli, G | 1 |
| Voltolini, S | 1 |
| Crugnola, M | 1 |
| Sebastio, P | 1 |
| Giuliani, N | 1 |
| Bastie, JN | 1 |
| Garcia, I | 1 |
| Terré, C | 1 |
| Cross, NC | 1 |
| Mahon, FX | 1 |
| Castaigne, S | 1 |
| Newton, HB | 1 |
| Scott, SR | 1 |
| Volpi, C | 1 |
| Hahn, BM | 1 |
| Schrell, UM | 1 |
| Sauer, R | 1 |
| Fahlbusch, R | 1 |
| Ganslandt, O | 1 |
| Grabenbauer, GG | 1 |
| Dincer, AP | 1 |
| Subramanian, S | 1 |
| Goksel, M | 1 |
| Perel, JM | 1 |
| McCarthy, C | 1 |
| Walker, O | 1 |
| Irving, I | 1 |
| Williams, B | 1 |
| Kennedy, GA | 1 |
| Iyoda, M | 1 |
| Ito, J | 1 |
| Ajiro, Y | 1 |
| Nagai, H | 1 |
| Uchida, J | 1 |
| Honda, H | 1 |
| Kuroki, A | 1 |
| Shibata, T | 1 |
| Kitazawa, K | 1 |
| Sugisaki, T | 1 |
| Egorin, MJ | 1 |
| Quinn, JA | 1 |
| Gururangan, I | 1 |
| Provenzale, JM | 1 |
| Dowell, JM | 1 |
| Badruddoja, MA | 1 |
| Lagattuta, TF | 1 |
| Kicielinski, KP | 1 |
| Dresemann, G | 1 |
| Friedman, AH | 1 |
| Salvado, AJ | 1 |
| Cramer, P | 1 |
| Thomale, UW | 1 |
| Okuducu, AF | 1 |
| Lemke, AJ | 1 |
| Stockhammer, F | 1 |
| Woiciechowsky, C | 1 |
| Bacher, U | 1 |
| Haferlach, T | 1 |
| Kern, W | 1 |
| Harich, HD | 1 |
| Schnittger, S | 1 |
| Haferlach, C | 1 |
| Wimazal, F | 1 |
| Baumgartner, C | 1 |
| Sonneck, K | 1 |
| Zauner, C | 1 |
| Geissler, P | 1 |
| Schur, S | 1 |
| Samorapoompichit, P | 1 |
| Müllauer, L | 1 |
| Födinger, M | 1 |
| Agis, H | 1 |
| Sperr, WR | 1 |
| Valent, P | 1 |
| Lipton, JH | 1 |
| Minden, M | 1 |
| Jeremic, B | 1 |
| Grujicic, D | 1 |
| Antunovic, V | 1 |
| Djuric, L | 1 |
| Stojanovic, M | 1 |
| Shibamoto, Y | 1 |
| Currie, JL | 1 |
| Blessing, JA | 1 |
| McGehee, R | 1 |
| Soper, JT | 1 |
| Berman, M | 1 |
| Nand, S | 1 |
| Stock, W | 1 |
| Godwin, J | 1 |
| Fisher, SG | 1 |
| Martinelli, G | 1 |
| Testoni, N | 1 |
| Zuffa, E | 1 |
| Visani, G | 1 |
| Zinzani, PL | 1 |
| Zaccaria, A | 1 |
| Farabegoli, P | 1 |
| Arpinati, M | 1 |
| Amabile, M | 1 |
| Gebbia, V | 1 |
| Majello, E | 1 |
| Testa, A | 1 |
| Pezzella, G | 1 |
| Giuseppe, S | 1 |
| Giotta, F | 1 |
| Riccardi, F | 1 |
| Fortunato, S | 1 |
| Colucci, G | 1 |
| Gebbia, N | 1 |
| Pulik, M | 1 |
| Lionnet, F | 1 |
| Genet, P | 1 |
| Petitdidier, C | 1 |
| Jary, L | 1 |
| Touahri, T | 1 |
| Kyritsis, AP | 2 |
| Yung, WK | 2 |
| Jaeckle, KA | 2 |
| Bruner, J | 1 |
| Gleason, MJ | 1 |
| Ictech, SE | 1 |
| Flowers, A | 1 |
| Levin, VA | 3 |
| Najean, Y | 2 |
| Rain, JD | 2 |
| Dresch, C | 1 |
| Goguel, A | 1 |
| Lejeune, F | 1 |
| Echard, M | 1 |
| Grange, MJ | 1 |
| Kaba, SE | 1 |
| Hess, K | 1 |
| Mercier, R | 1 |
| Dakhil, S | 1 |
| Prados, MD | 1 |
| Larson, DA | 1 |
| Lamborn, K | 1 |
| McDermott, MW | 1 |
| Sneed, PK | 1 |
| Wara, WM | 1 |
| Chang, SM | 1 |
| Mack, EE | 1 |
| Krouwer, HG | 1 |
| Chandler, KL | 1 |
| Warnick, RE | 1 |
| Davis, RL | 1 |
| Rabbitt, JE | 1 |
| Malec, M | 1 |
| Gutin, PH | 1 |
| Phillips, TL | 1 |
| Wilson, CB | 1 |
| Rose, PG | 1 |
| Bundy, BN | 1 |
| Watkins, EB | 1 |
| Thigpen, JT | 1 |
| Deppe, G | 1 |
| Maiman, MA | 1 |
| Clarke-Pearson, DL | 1 |
| Insalaco, S | 1 |
| Silverstein, MN | 1 |
| List, M | 1 |
| Humerickhouse, R | 1 |
| Dolan, ME | 1 |
| Sulzen, L | 1 |
| Hsieh, YC | 1 |
| Polák, J | 1 |
| Koza, V | 1 |
| Cetkovský, P | 1 |
| Haskovec, C | 1 |
| Bundschuh, S | 1 |
| Biermann, T | 1 |
| Roessler, G | 1 |
| Wasmus, M | 1 |
| Zankovich, R | 1 |
| Schaefer, HE | 1 |
| Brière, J | 2 |
| Guilmin, F | 1 |
| Tóthová, E | 1 |
| Fricová, M | 1 |
| Stecová, N | 1 |
| Hlebasková, M | 1 |
| Kafková, A | 1 |
| Raffac, S | 1 |
| Guman, T | 1 |
| Svorcová, E | 1 |
| Nebesnáková, E | 1 |
| Stamatopoulos, K | 1 |
| Yataganas, X | 1 |
| Papadaki, T | 1 |
| Paterakis, G | 1 |
| Hirose, Y | 1 |
| Masaki, Y | 1 |
| Sugai, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)[NCT01259856] | Phase 3 | 168 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms[NCT05850273] | 50 participants (Anticipated) | Observational | 2023-03-16 | Recruiting | |||
| An Integrated European Platform to Conduct Translational Studies in Myelodysplastic Syndromes Based on the EuroBloodNet Infrastructure[NCT04174547] | 8,670 participants (Anticipated) | Observational | 2019-09-30 | Recruiting | |||
| A Randomised Trial to Compare Aspirin vs Hydroxyurea/Aspirin in 'Intermediate Risk' Primary Thrombocythaemia and Aspirin Only With Observation in 'Low Risk'Primary Thrombocythaemia[NCT00175838] | 1,398 participants (Actual) | Interventional | 1997-07-31 | Completed | |||
| Clinical Study Protocol No. VIA-2291-01, A Phase 2 Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-ranging Study of the Effect of VIA-2291 on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event[NCT00358826] | Phase 2 | 191 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma[NCT00354913] | Phase 2 | 21 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| The Effect of Prophylactic Swallowing Exercises on Head and Neck Cancer Patients[NCT01349309] | 26 participants (Actual) | Interventional | 2007-06-30 | Completed | |||
| Study on Adaptive Radiotherapy and Multimodal Information of Cervical Cancer Assisted by Artificial Intelligence[NCT04022018] | 122 participants (Anticipated) | Interventional | 2019-12-18 | Recruiting | |||
| AVF3963s Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer[NCT00600210] | Phase 2 | 0 participants (Actual) | Interventional | 2008-01-31 | Withdrawn (stopped due to low patient accrual) | ||
| A Prospective Phase II Study of Prophylactic TPO Combined With Bone Marrow-Sparing Intensity-Modulated Radiotherapy to Reduce Platelet Inhibition in Patients With Esophageal Cancer Undergoing Concurrent Chemoradiotherapy[NCT05944809] | Phase 2 | 27 participants (Anticipated) | Interventional | 2023-07-15 | Not yet recruiting | ||
| A Phase III Randomized Clinical Trial to Study the Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Uterine Cervix.[NCT03256916] | Phase 3 | 348 participants (Anticipated) | Interventional | 2018-01-16 | Recruiting | ||
| Phase II Trial To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer Cervix[NCT04789941] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | ||
| Safety and Efficacy of Gemcitabine Based Neoadjuvant Chemotherapy Followed by Chemoradiation in Locally Advanced Cervical Cancer Patients and Association With Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression[NCT02309658] | Phase 2 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Randomized Phase III Clinical Trial of Weekly Versus Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer[NCT01561586] | Phase 3 | 374 participants (Anticipated) | Interventional | 2012-03-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in the Total Symptom Score which assessed improvement in disease symptoms measured by the change in TSS from the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) instrument being used in this study from baseline to 12 months. This 19 item instrument includes the previously validated 9 item brief fatigue inventory (BFI), symptoms related to splenomegaly, inactivity, cough, night sweats, pruritus, bone pains, fevers, weight loss, and an overall quality of life assessment. Each item is scored from 0-10 with full scale from 0-190, with higher scores mean worse symptoms. (NCT01259856)
Timeframe: baseline and 12 months
| Intervention | score on a scale (Mean) |
|---|---|
| PEGASYS | 1.16 |
| Hydroxyurea | -1.0 |
(NCT01259856)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| PEGASYS | 1 |
| Hydroxyurea | 1 |
Number of participants with Complete Remission after 12 months of therapy assessed by hematologic response rates two strata of patients with high risk polycythemia vera (PV) or high risk essential thrombocythemia (ET). Complete remission means no evidence of disease. (NCT01259856)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Essential Thrombocythemia | Polycythemia Vera | |
| Hydroxyurea | 19 | 13 |
| PEGASYS | 17 | 12 |
Number of Participants with Grade 3 and Grade 4 Hematological and Non-hematological Events using the Common Terminology Criteria for Adverse Events (CTCAE) 4.0 to assess the toxicity, safety and tolerability of therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea). (NCT01259856)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Grade 3 Hematological event | Grade 4 Hematological event | Grade 3 Non-hematological event | Grade 4 Non-hematological event | |
| Hydroxyurea | 2 | 0 | 14 | 3 |
| PEGASYS | 3 | 0 | 27 | 2 |
Number of participants with Partial Remission after 12 months of therapy assessed by hematologic response rates two strata of patients with high risk polycythemia vera (PV) or high risk essential thrombocythemia (ET). Partial Remission means decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment. (NCT01259856)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Essential Thrombocythemia | Polycythemia Vera | |
| Hydroxyurea | 11 | 17 |
| PEGASYS | 10 | 25 |
"Survival and incidence of development of myelodysplastic syndrome, myelofibrosis, or leukemic transformation after therapy~To estimate survival and incidence of development of myelodysplastic syndrome, myelofibrosis, or leukemic transformation after therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea) by capturing the rate of progression to a more advanced myeloid malignancy." (NCT01259856)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Death | Progression to MF | |
| Hydroxyurea | 1 | 0 |
| PEGASYS | 0 | 0 |
(NCT00358826)
Timeframe: Baseline and 12 weeks
| Intervention | mg/L (Median) |
|---|---|
| VIA-2291 25 mg | -0.2 |
| VIA-2291 50 mg | -0.1 |
| VIA-2291 100 mg | -0.3 |
| Placebo | -0.2 |
(NCT00358826)
Timeframe: Baseline and 24 weeks
| Intervention | mg/L (Median) |
|---|---|
| VIA-2291 25 mg MDCT Substudy | -0.4 |
| VIA-2291 50 mg MDCT Substudy | -0.2 |
| VIA-2291 100 mg MDCT Substudy | -0.4 |
| Placebo MDCT Substudy | 0.0 |
Urinary LTE4 is expressed in pg per mg Creatinine (pg/mg Cr) to normalize for renal excretion rate (NCT00358826)
Timeframe: Baseline and 12 weeks
| Intervention | pg/mg Cr (Least Squares Mean) |
|---|---|
| VIA-2291 25 mg | -26.8 |
| VIA-2291 50 mg | -38.6 |
| VIA-2291 100 mg | -56.5 |
| Placebo | 8.4 |
Plaque density is expressed in Hounsfield Units (HU) (NCT00358826)
Timeframe: Baseline and 24 weeks
| Intervention | HU (Least Squares Mean) |
|---|---|
| VIA-2291 25 mg | 19.11 |
| VIA-2291 50 mg | 7.39 |
| VIA-2291 100 mg | 12.22 |
| Placebo | 12.42 |
(NCT00358826)
Timeframe: Baseline and 24 weeks
| Intervention | mm^3 (Least Squares Mean) |
|---|---|
| VIA-2291 25 mg MDCT Substudy | -1.55 |
| VIA-2291 50 mg MDCT Substudy | -5.6 |
| VIA-2291 100 mg MDCT Substudy | 0.15 |
| Placebo MDCT Substudy | 2.83 |
(NCT00358826)
Timeframe: Baseline and 24 weeks
| Intervention | Percentage (Least Squares Mean) |
|---|---|
| VIA-2291 25 mg | -0.11 |
| VIA-2291 50 mg | 11.45 |
| VIA-2291 100 mg | 2.36 |
| Placebo | 1.19 |
(NCT00358826)
Timeframe: Baseline and 12 weeks
| Intervention | pg/mL (Least Squares Mean) |
|---|---|
| VIA-2291 25 mg | -88126 |
| VIA-2291 50 mg | -95703 |
| VIA-2291 100 mg | -122668 |
| Placebo | -20843 |
Time in months from the start of study treatment to date of death due to any cause. Patients alive at last follow-up are censored as of that follow-up date. Median OS was estimated using a Kaplan-Meier curve. (NCT00354913)
Timeframe: From the date of study treatment initiation to the date of death from any cause, assessed up to 69 months.
| Intervention | months (Median) |
|---|---|
| Imatinib Mesylate+Hydroxyurea | 66 |
Time in months from the start of study treatment to the date of first progression according to Macdonald criteria, or to death due to any cause. Patients alive who had not progressed as of the last follow-up had PFS censored at the last follow-up date. Median PFS was estimated using a Kaplan-Meier curve. (NCT00354913)
Timeframe: From the date of study treatment initiation to the date of the first documented progression or death from any cause, whichever came first, assessed up to 69 months.
| Intervention | months (Median) |
|---|---|
| Imatinib Mesylate+Hydroxyurea | 7 |
Percentage of participants with an objective response (complete response or partial response). Per modified Macdonald criteria and assessed by MRI, complete response (CR) was the disappearance of all target lesions and partial response (PR) was a ≥50% decrease in the sum of the longest diameter of target lesions. Objective response = CR+PR. (NCT00354913)
Timeframe: 69 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Imatinib Mesylate+Hydroxyurea | 0 |
Percentage of participants surviving six months from the start of study treatment without progression of disease. PFS was defined as the time from the date of study treatment initiation to the date of the first documented progression according to the Macdonald criteria, or death due to any cause. (NCT00354913)
Timeframe: From the date of study treatment initiation to the date of the first documented progression or death from any cause, whichever came first, assessed up to 69 months. For each participant, PFS was assessed at 6 months after treatment initiation.
| Intervention | percentage of participants (Number) |
|---|---|
| Imatinib Mesylate+Hydroxyurea | 61.9 |
27 reviews available for hydroxyurea and Disease Exacerbation
| Article | Year |
|---|---|
Current and emerging treatments for sickle cell disease.
Topics: Acute Chest Syndrome; Acute Disease; Analgesics, Opioid; Anemia, Sickle Cell; Anti-Bacterial Agents; | 2019 |
Novel agents for the treatment of polycythemia vera: an insight into preclinical research and early phase clinical trials.
Topics: Animals; Disease Progression; Drug Development; Histone Deacetylase Inhibitors; Humans; Hydroxyurea; | 2020 |
Givinostat: an emerging treatment for polycythemia vera.
Topics: Animals; Carbamates; Disease Progression; Histone Deacetylase Inhibitors; Humans; Hydroxyurea; Janus | 2020 |
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Dis | 2017 |
Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Cell Communication; Cerebrovascular Disorders; Disease Pro | 2018 |
A 66-year-old man with hydroxycarbamide induced pneumonitis.
Topics: Administration, Oral; Aged; Disease Progression; Dose-Response Relationship, Drug; Drug Administrati | 2018 |
[Treatment of essential thrombocythemia].
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cell Transformation, Neoplastic; Disease Progress | 2013 |
Sickle cell disease: time for a closer look at treatment options?
Topics: Africa; Anemia, Sickle Cell; Brain Damage, Chronic; Cardiovascular Diseases; Chelation Therapy; Chro | 2013 |
Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment.
Topics: Adolescent; Age of Onset; Anticoagulants; Child; Child, Preschool; Clone Cells; Disease Progression; | 2013 |
Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Disease Progression; Humans; Hydroxyurea; Ja | 2014 |
Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
Topics: Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cost of Illness; Disease Progression | 2014 |
Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms.
Topics: Bone Marrow; Combined Modality Therapy; Disease Progression; Female; Fibrosis; Humans; Hydroxyurea; | 2015 |
Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.
Topics: Aspirin; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Hydroxyurea; Incid | 2015 |
Pharmacotherapy of essential thrombocythemia.
Topics: Age Factors; Antineoplastic Agents; Aspirin; Disease Progression; Humans; Hydroxyurea; Interferon-al | 2008 |
Pathogenesis and management of essential thrombocythemia.
Topics: Acute Disease; Aged; Aspirin; Clone Cells; Disease Management; Disease Progression; Humans; Hydroxyu | 2009 |
Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.
Topics: Aged; Agranulocytosis; Alkylating Agents; Clinical Trials as Topic; Combined Modality Therapy; Disea | 2006 |
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Topics: Acute Disease; Age Factors; Alkylating Agents; Anticoagulants; Aspirin; Busulfan; Disease Management | 2012 |
Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.
Topics: Adrenal Cortex Hormones; Adult; Bone Marrow Examination; Cell Lineage; Cladribine; Clinical Trials a | 2012 |
Drug treatment for spinal muscular atrophy types II and III.
Topics: Acetylcarnitine; Adolescent; Amines; Child; Child, Preschool; Creatine; Cyclohexanecarboxylic Acids; | 2012 |
Chronic pain perspectives: Sickle cell disease: Gaining control over the pain.
Topics: Adaptation, Psychological; Adult; Analgesia, Patient-Controlled; Analgesics, Opioid; Anemia, Sickle | 2012 |
Simultaneous occurrence of a t(9;22) (Ph) with a t(2;11) in a patient with CML and emergence of a new clone with the t(2;11) alone after imatinib mesylate treatment.
Topics: Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 2; Clinical | 2003 |
Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
Topics: Acute Disease; Adult; Aged; Alkylating Agents; Cell Transformation, Neoplastic; Child; Clinical Tria | 2004 |
The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antiviral Agents; Disease Progression; Female; | 2004 |
Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Disease Progres | 2005 |
Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
Topics: Actuarial Analysis; Acute Disease; Carcinoma; Cause of Death; Disease Progression; Follow-Up Studies | 1996 |
Treatment of polycythaemia vera and essential thrombocythaemia.
Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; In | 1998 |
Management of patients with essential thrombocythemia: current concepts and perspectives.
Topics: Adult; Aged; Aspirin; Case Management; Clinical Trials as Topic; Diagnosis, Differential; Disease Pr | 2001 |
18 trials available for hydroxyurea and Disease Exacerbation
| Article | Year |
|---|---|
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Topics: Disease Progression; Humans; Hydroxyurea; Interferon-alpha; Polycythemia Vera; Thrombocythemia, Esse | 2022 |
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Topics: Disease Progression; Humans; Hydroxyurea; Interferon-alpha; Polycythemia Vera; Thrombocythemia, Esse | 2022 |
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Topics: Disease Progression; Humans; Hydroxyurea; Interferon-alpha; Polycythemia Vera; Thrombocythemia, Esse | 2022 |
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Topics: Disease Progression; Humans; Hydroxyurea; Interferon-alpha; Polycythemia Vera; Thrombocythemia, Esse | 2022 |
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Drug Resistance; Female; Hemorrhage; Humans; Hy | 2017 |
Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features.
Topics: Adult; Aspirin; Australia; Disease Progression; Dose-Response Relationship, Drug; Drug Administratio | 2018 |
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
Topics: Aged; Aged, 80 and over; Alkylating Agents; Blood Cell Count; Busulfan; Comorbidity; Disease Progres | 2014 |
Effect of treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) on coronary plaque progression: a serial CT angiography study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Computed Tomography Angiography; Coronary V | 2017 |
Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Fem | 2008 |
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2011 |
Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease | 2012 |
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2012 |
Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Female; Humans; Hydroxyurea; Karnofsky Perf | 2002 |
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2005 |
Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Etopo | 1996 |
Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
Topics: Adenocarcinoma; Administration, Oral; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplast | 1996 |
Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
Topics: Actuarial Analysis; Acute Disease; Carcinoma; Cause of Death; Disease Progression; Follow-Up Studies | 1996 |
TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 1997 |
Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group.
Topics: Actuarial Analysis; Aged; Alkylating Agents; Combined Modality Therapy; Disease Progression; Follow- | 1997 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 1999 |
Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease Progre | 2000 |
65 other studies available for hydroxyurea and Disease Exacerbation
| Article | Year |
|---|---|
Sequential development of human herpes virus 8-positive diffuse large B-cell lymphoma and chronic myelomonocytic leukemia in a 59 year old female patient with hemoglobin SC disease.
Topics: Antisickling Agents; Cell Transformation, Neoplastic; Disease Progression; Fatal Outcome; Female; He | 2019 |
Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Child; Disease Progress | 2019 |
Pediatric Hematologists Report Infrequent Prognosis Discussions in the Routine Care of Children with Sickle Cell Disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Disease Progression; Female; Health Car | 2020 |
Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection.
Topics: Acute Chest Syndrome; Adult; Anemia, Sickle Cell; Antisickling Agents; COVID-19; Disease Progression | 2021 |
Treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened Kidney Function.
Topics: Aged; Calreticulin; Creatinine; Disease Progression; Female; Humans; Hydroxyurea; Janus Kinase 2; Ki | 2021 |
Fanconi anemia proteins participate in a break-induced-replication-like pathway to counter replication stress.
Topics: Aneuploidy; Animals; Bone Marrow Failure Disorders; Cell Line, Transformed; Chickens; Chromosome Bre | 2021 |
ALOX5-5-HETE promotes gastric cancer growth and alleviates chemotherapy toxicity via MEK/ERK activation.
Topics: Analysis of Variance; Antineoplastic Agents; Arachidonate 5-Lipoxygenase; Cell Proliferation; Cell S | 2021 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; | 2017 |
38-Year-Old Man With Asthma and Eosinophilia.
Topics: Adult; Anti-Asthmatic Agents; Antineoplastic Agents; Asthma; Diagnosis, Differential; Disease Progre | 2017 |
Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Disease Progression; Female; Gene Frequency; High-Throughpu | 2018 |
Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Biological Specimen Banks; Blood Transfusion; Body Fluids; C | 2018 |
Immunological role of CD4
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; CD28 Antigens; CD4-Positive T-Lymphocytes; Chi | 2018 |
Evidence of hydroxyurea activity in children with pretreated desmoid-type fibromatosis: A new option in the armamentarium of systemic therapies.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Disease Progression; Female; Fibr | 2019 |
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Topics: Adult; Aspirin; Bone Marrow; Busulfan; Disease Management; Disease Progression; Hemorrhage; Humans; | 2019 |
Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia.
Topics: Adolescent; Albuminuria; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Disease | 2019 |
Does hydroxycarbamide therapy really induce leukemic transformation in patients with essential thrombocythemia?
Topics: Cell Transformation, Neoplastic; Disease Progression; Humans; Hydroxyurea; Thrombocythemia, Essentia | 2019 |
Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, | 2019 |
Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
Topics: Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Cerebral Infarction; Cerebr | 2013 |
Cutaneous involvement by post-polycythemia vera myelofibrosis.
Topics: Aged; Aspirin; Biopsy; Cell Lineage; Disease Progression; Drug Therapy, Combination; Fibrosis; Hemat | 2014 |
Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease.
Topics: Acute Chest Syndrome; Adolescent; Adult; Aged; Albuminuria; Anemia, Sickle Cell; Angiotensin-Convert | 2014 |
Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 6; Combined Modality Ther | 2014 |
Hyperfiltration is associated with the development of microalbuminuria in patients with sickle cell anemia.
Topics: Adolescent; Adult; Age Factors; Albuminuria; Anemia, Sickle Cell; Biomarkers; Disease Progression; F | 2014 |
[Current management of thalassemia intermedia].
Topics: Allografts; alpha-Thalassemia; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Combined Moda | 2014 |
Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.
Topics: Alleles; Bone Marrow; Disease Progression; Humans; Hydroxyurea; Janus Kinase 2; Mutation; Polycythem | 2015 |
Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report.
Topics: Aged; Aspergillosis; Blood Transfusion; Danazol; Disease Progression; Drug Resistance; Fatal Outcome | 2015 |
Can pegylated interferon improve the outcome of polycythemia vera patients?
Topics: Adolescent; Adult; Aged; Disease Progression; Female; Humans; Hydroxyurea; Interferon-alpha; Janus K | 2017 |
Pleural effusion heralds acute leukemic transformation of chronic myelomonocytic leukemia.
Topics: Blast Crisis; Bone Marrow; Disease Progression; Fatal Outcome; Female; Humans; Hydroxyurea; Leukemia | 2008 |
Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; beta 2-Microglobulin; Disease Progression; Enzyme Inhibit | 2009 |
A fertile XY/XX chimeric male with chronic myeloid leukemia in a minor 46,XX cell line and a history of polycythemia vera and trisomy 9 in the major 46,XY cell line.
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Chimera; Chromosomes, Human, Pair 9; Chromosom | 2009 |
Sun, drugs, and skin cancer: a continuing saga.
Topics: Aged, 80 and over; Disease Progression; Female; Humans; Hydroxyurea; Neoplasms, Radiation-Induced; N | 2010 |
Treatment outcome in a cohort of young patients with polycythemia vera.
Topics: Adult; Antineoplastic Agents; Aspirin; Cohort Studies; Combined Modality Therapy; Disease Progressio | 2010 |
Chronic neutrophilic leukaemia: an Egyptian case.
Topics: Antineoplastic Agents; Diagnosis, Differential; Disease Progression; Egypt; Fatal Outcome; Humans; H | 2009 |
Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood.
Topics: Aged; Antigens, CD34; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Disease Progression; Fus | 2012 |
Combined blood transfusion and hydroxycarbamide in children with sickle cell anaemia.
Topics: Adolescent; Anemia, Sickle Cell; Blood Transfusion; Brain Ischemia; Cerebral Infarction; Cerebral Re | 2013 |
Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Chroni | 2003 |
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2003 |
The optimal management of polycythaemia vera.
Topics: Disease Progression; Humans; Hydroxyurea; Nucleic Acid Synthesis Inhibitors; Platelet Count; Polycyt | 2003 |
Trisomy X in Philadelphia chromosome-negative cells during the course of Philadelphia chromosome-positive chronic myelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Chromosomes, Human, X; Clone Cells; Disease Progression; Female; Human | 2003 |
Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients.
Topics: Biopsy; Bone Marrow; Busulfan; Disease Progression; Follow-Up Studies; Humans; Hydroxyurea; Interfer | 2003 |
Chronic myeloid leukemia with osteolytic bone involvement.
Topics: Adult; Antineoplastic Agents; Blast Crisis; Disease Progression; Humans; Hydroxyurea; Leukemia, Myel | 2003 |
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2003 |
Towards a rational treatment of essential thrombocythemia, despite limited evidence and old prejudices.
Topics: Adult; Cohort Studies; Disease Progression; Evidence-Based Medicine; Expert Testimony; Female; Hemor | 2004 |
e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Fusion Proteins, b | 2004 |
Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene.
Topics: Benzamides; Biomarkers; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 5; Disease Progression | 2004 |
Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Drug Evaluation; Female; Follow-Up Studies; | 2004 |
Polycythemia vera with uncommon presentations.
Topics: Adult; Aged; Anemia, Hypochromic; beta-Thalassemia; Case Management; Disease Progression; Genotype; | 2003 |
Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamid | 2005 |
[Focal segmental glomerulosclerosis in a patient with polycythemia vera].
Topics: Aged; Disease Progression; Female; Glomerulosclerosis, Focal Segmental; Humans; Hydroxyurea; Nitroso | 2005 |
An atypical spinal meningioma with CSF metastasis: fatal progression despite aggressive treatment. Case report.
Topics: Adult; Antineoplastic Agents; Cervical Vertebrae; Decompression, Surgical; Disease Progression; Fata | 2005 |
A case of chronic myeloproliferative syndrome followed by precursor T-cell acute lymphoblastic leukemia.
Topics: Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosome Banding; Chromosome Painting; Di | 2007 |
Mixed-lineage eosinophil/basophil crisis in MDS: a rare form of progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Basophils; Disease Progression; Eosinophils; | 2008 |
CML may not be part of HUS.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Disease Progression; Gr | 1995 |
Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Carmustine; Ch | 1994 |
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Topics: Acute Disease; Anemia, Refractory, with Excess of Blasts; Busulfan; Cell Transformation, Neoplastic; | 1996 |
FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Bone Marrow Transplantati | 1996 |
Acute myeloid leukemia evolving from polycythemia vera in a patient treated with hydroxyurea.
Topics: Adult; Bone Marrow; Disease Progression; Fatal Outcome; Humans; Hydroxyurea; Leukemia, Monocytic, Ac | 1996 |
Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Pr | 1996 |
Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1998 |
Is hydroxyurea leukemogenic in essential thrombocythemia?
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Bone Marrow; Busulfan; Chromosome Aberrations; Chr | 1998 |
An accelerrated-phase CML patient with e19a2 junction of BCR/ABL gene - the first case of transplanted CML with micro bcr.
Topics: Abortion, Therapeutic; Adult; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Diseas | 2000 |
Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia. Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Bone Marrow; Busulfan; Disease Pro | 2000 |
Myeloproliferative syndromes. Current opinions from the European Hematology Association Working Group on Myeloproliferative Disorders.
Topics: Aspirin; Bone Marrow Examination; Clinical Trials as Topic; Clone Cells; Congresses as Topic; Diseas | 2001 |
Leukemic transformation of polycythemia vera after treatment with hydroxyurea with abnormalities of chromosome 17.
Topics: Antineoplastic Agents; Bone Marrow Cells; Chromosome Aberrations; Chromosomes, Human, Pair 17; Disea | 2001 |
Unusually prolonged survival of a case of acute megakaryoblastic leukemia secondary to long-standing polycythemia vera.
Topics: Bone Marrow; Combined Modality Therapy; Disease Progression; Erythrocyte Transfusion; Female; Humans | 2002 |
Leukemic transformation with trisomy 8 in essential thrombocythemia: a report of four cases.
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; Busulfan; Cell Transformation, Neoplastic; Chromosomes, | 2002 |